Please assess the completion status of the following clinical trial:

Trial Title: Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: ≥ 18 and ≤ 75 years, both male and female;~2. Non-radical hepatectomy has been performed for hepatocellular carcinoma;~3. The hepatocellular carcinoma has been confirmed by pathological examination;~4. The liver and kidney function satisfies the following conditions within 15 days after surgery (excluding day 15): aspartate aminotransferase(AST), glutamic-oxalacetic transaminase(ALT)\<3 upper limit of normal(ULN), total bilirubin ≤2 ULN, serum creatinine \<1.5 ULN;~5. Other laboratory tests meet the following requirements within 15 days after surgery (excluding day 15): Hb≥9g/dl, platelet count≥60×109/L, neutrophil count\> 1.5×109/L;~6. The expected survival time ≥12 weeks;~7. The subjects volunteer to sign the informed consent.~Exclusion Criteria:~1. Non-hepatocellular carcinoma patients;~2. Those who received radical hepatectomy;~3. Those with hepatic decompensation;~4. Pregnant or lactating women;~5. Those with HIV infection or AIDS-associated diseases;~6. Those with severe acute and chronic diseases, such as infection, diabetes cardiac insufficiency, pulmonary insufficiency, renal insufficiency;~7. Those who can not take drugs by oral route; or those develop serious adverse drug reaction;~8. Drug abusers or those with psychological or mental diseases that may interfere with study compliance;~9. Conditions that are considered not suitable for this study investigators.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Test group (Type: EXPERIMENTAL): Test group: Adjuvant therapy + Huaier Granule group.Administration: the Huaier Granule Electuary should be orally taken from the 15th day after surgery. Usage: Huaier Granule Electuary is continuously taken three times per day, 20g per time, until 144 weeks after surgery or until study termination Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment
- Control group: adjuvant therapy (Type: NO_INTERVENTION): Control group: adjuvant therapy Adjuvant therapy: the adjuvant therapies are not limited, and for example, all the following treatments can be applied according to the individual's condition and guidelines of the research center: ablation therapy, immunotherapy, chemotherapy, radiotherapy, and Chinese herbs, as well as programs and medications that are used for post-operative liver protection and antiviral treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).